News
Contacts:
Cephalon:
Robert
Grupp
610-738-6402
East-West Center
Susan
Kreifels
808-944-7176
kreifels@EastWestCenter.org
For Immediate
Release
Cephalon General Counsel John Osborn Appointed
To East-West Center Board of Governors
West Chester, PA – September 23, 2004 – John E. Osborn, Senior Vice President and General Counsel at Cephalon, Inc., has been appointed to a three-year term on the Board of Governors of the East-West Center by U.S. Secretary of State Colin Powell.
At Cephalon, Osborn is responsible for managing all legal, intellectual property, government and public affairs matters. He has long been active in government, politics and community affairs. Prior to joining Cephalon, he served as Special Assistant to the Legal Adviser with the U.S. Department of State during the George H.W. Bush Administration, and worked in the offices of U.S. Representative Jim Leach of Iowa and the late U.S. Senator John Heinz of Pennsylvania.
Osborn worked on the 1980 and 1988 Bush presidential campaigns, and has been active
in the Bush-Cheney 2004 campaign, serving as a member of Pennsylvania Technology Executives for Bush as well as on the campaign’s Delaware state steering committee. Among other community activities, he is a member of the Corporate Executive Board of the Philadelphia Museum of Art, a member of the steering committee of the Eisenhower Fellowships’ Philadelphia Regional Leadership Initiative, and a trustee of the Delaware Art Museum and Tower Hill School in Wilmington, Delaware. He also holds a visiting appointment in politics at Princeton University, where he is a research fellow at the University’s Bobst Center for Peace and Justice.
“I am honored and pleased to have been given this opportunity by the Secretary of State to contribute to the important work of this fine organization,” Osborn said. “The relationships between the United States and the nations of the Asia-Pacific region will continue to be critically important in the 21st century, and the Center is working to better understand issues of common concern.”
-- more --
The East-West Center
The East-West Center, based in Honolulu, Hawaii and with offices in Washington DC, is an internationally recognized education and research organization established by the U.S.
Congress in 1960 to strengthen relations and understanding among the nations of Asia, the Pacific and the United States. The Center promotes the development of a stable, prosperous and peaceful Asia Pacific community through cooperative study, research and professional development.
The late Senator William V. Roth of Delaware formerly served on the 18-member Board of Governors, and the Board presently includes former U.S. Senator Nancy Landon Kassebaum, and former U.S. Representative Patricia Saiki of Hawaii.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer and pain.
Cephalon currently employs more than 2,000 people in the United States and Europe. U.S. sites include the company’s headquarters in West Chester, Pennsylvania, and offices and manufacturing facilities in Salt Lake City, Utah and Eden Prairie, Minnesota. Cephalon’s major European offices are located in Guildford, England, Martinsried, Germany, and Maisons-Alfort, France.
The company currently markets three proprietary products in the United
States: PROVIGIL® (modafinil) Tablets [C-IV], GABITRIL® (tiagabine hydrochloride) and ACTIQ® (oral transmucosal fentanyl citrate)
[C-II] and more than 20 products internationally. Further information about Cephalon and full prescribing
information on its U.S. products is available at www.cephalon.com
or by calling 1-800-896-5855.
In addition to
historical facts or statements of current condition, this press release may
contain forward-looking statements. Forward-looking statements provide
Cephalon’s current expectations or forecasts of future events. You may identify
some of these forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,”
“believe” or other words and terms of similar meaning. Cephalon’s performance
and financial results could differ materially from those reflected in these
forward-looking statements due to general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical industries
as well as more specific risks and uncertainties facing Cephalon such as those
set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Given these risks and uncertainties, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
Furthermore, Cephalon does not intend to update publicly any forward-looking
statement, except as required by law. The Private Securities Litigation Reform
Act of 1995 permits this discussion.
# # #